On March 10, 2022 BioCurity, a preclinical biotech company focused on developing novel mechanism-based nanoparticle drugs designed to transform radiation therapy for cancer patients worldwide, reported the Company’s presentation at the American College of Radiation Oncology (ACRO) 2022 Summit on March 11, 2022, from 12:00-1:00pm EST at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida (Press release, BioCurity Pharmaceuticals, MAR 10, 2022, View Source [SID1234609926]). Details of the presentations are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Harnessing Cerium Oxide Nanoparticles Combined with Tolfenamic Acid to Sensitize Head and Neck Cancer to Radiation
Session: Poster Walk with Professors – Bonnet
Presenter: Cheryl Baker, PhD, Scientific Co-Founder, BioCurity
The agenda for the ACRO 2022 Summit can be found here.
"Our IV and topical drug candidate consistent with positive preclinical data in lead indications such as head and neck, lung, and breast cancer was demonstrated to prevent radiation side effects without impairing the effectiveness of radiation killing cancer cells and shrinking tumors. BioCurity’s discovery could have a material positive impact for the millions of cancer patients that undergo radiation therapy annually. Approximately 70% of head and neck cancer patients treated with radiation therapy will develop severe oral mucositis, limiting their ability to eat or drink. We look forward to sharing our positive preclinical data with the leaders in radiation oncology at ACRO this week," said Dr. Cheryl Baker, PhD, Scientific Co-Founder, and a Board Member of BioCurity.
About Cerium Oxide Nanoparticles
The production of hydrogen peroxide, a Reactive Oxygen Species (ROS) from radiation is a critical function for how radiation damages the DNA of cells of the tissue it passes through. BioCurity’s cerium oxide nanoparticles possess fast catalase activity in a normal tissue’s neutral pH environment and reduces radiation-induced hydrogen peroxide to molecular oxygen, thereby preventing radiation damage of normal tissue. BioCurity’s cerium oxide nanoparticles also possess superoxide dismutase activity in a cancerous tissue’s acidic pH environment and converts superoxide to hydrogen peroxide, thereby enhancing radiation-induced ROS damage of cancerous tissue.
BioCurity’s extensive preclinical studies in models of head and neck, lung, breast, pancreatic, prostate, and colorectal cancer show cerium oxide nanoparticles are regenerative and are not consumed in the reaction. Administration of cerium oxide nanoparticles at 1,000 times the effective dose did not produce toxicity in a small animal model.